Compare BGSF & ASRT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BGSF | ASRT |
|---|---|---|
| Founded | 2007 | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Professional Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 63.4M | 76.0M |
| IPO Year | 2013 | 2004 |
| Metric | BGSF | ASRT |
|---|---|---|
| Price | $5.99 | $12.18 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | $9.00 | ★ $35.00 |
| AVG Volume (30 Days) | 19.9K | ★ 33.6K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 33.45% | N/A |
| EPS Growth | 67.37 | ★ 95.07 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $272,499,000.00 | $124,961,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $3.14 | $1.42 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $2.91 | $0.51 |
| 52 Week High | $8.20 | $12.95 |
| Indicator | BGSF | ASRT |
|---|---|---|
| Relative Strength Index (RSI) | 56.96 | 61.08 |
| Support Level | $5.93 | $0.67 |
| Resistance Level | $6.38 | $12.75 |
| Average True Range (ATR) | 0.25 | 0.52 |
| MACD | -0.03 | -0.18 |
| Stochastic Oscillator | 47.20 | 78.31 |
BGSF Inc is a national provider of consulting, managed services, and professional workforce solutions. two segments: Property Management and Professional. In the Property Management segment is a provider of office and maintenance talent. The Professional segment provides IT professionals with expertise in SAP, Workday, Peoplesoft, Hyperion, Oracle, One Stream, cyber, project management, managed services, and other IT workforce solutions to client partners on a national basis. The group generates the majority of its revenue from the Professional segment.
Assertio Holdings Inc is a pharmaceutical company. It is engaged in providing solutions to advance patient care in the areas of neurology, orphan and specialty medicines. The company markets three FDA-approved products for various neurological conditions including Gralise, tablets for the management of postherpetic neuralgia; CAMBIA, for acute treatment of migraine attacks with or without aura in adults of age or older and Zipsor, liquid-filled capsules for relief of mild to moderate pain.